Novo Nordisk A/S (NVO): Price and Financial Metrics
Novo Nordisk A/S (NVO)
Today's Latest Price: $66.86 USD
Updated Aug 13 5:29pm
Add NVO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
NVO Stock Summary
- NVO has a higher market value than 98.99% of US stocks; more precisely, its current market capitalization is $158,191,511,000.
- Novo Nordisk A S's stock had its IPO on January 1, 1986, making it an older stock than 92.9% of US equities in our set.
- In terms of volatility of its share price, NVO is more volatile than only 1.86% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Novo Nordisk A S are GSK, AZN, CMI, PHG, and CLRO.
- NVO's SEC filings can be seen here. And to visit Novo Nordisk A S's official web site, go to www.novonordisk.com.
NVO Stock Price Chart Technical Analysis Charts
NVO Price/Volume Stats
| Current price | $66.86 | 52-week high | $68.96 |
| Prev. close | $67.09 | 52-week low | $48.60 |
| Day low | $66.57 | Volume | 811,613 |
| Day high | $67.14 | Avg. volume | 1,697,536 |
| 50-day MA | $66.01 | Dividend yield | 1.67% |
| 200-day MA | $61.31 | Market Cap | 157.44B |
Novo Nordisk A/S (NVO) Company Bio
Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The company was founded in 1925 and is based in Bagsvaerd, Denmark.
NVO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $66.86 | $262.07 | 302% |
Below please find a table outlining a discounted cash flow forecast for NVO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Novo Nordisk A S ranked in the 74th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 304%. The most interesting components of our discounted cash flow analysis for Novo Nordisk A S ended up being:
- The company has produced more trailing twelve month cash flow than 99.07% of its sector Healthcare.
- The business' balance sheet suggests that 0% of the company's capital is sourced from debt; this is greater than merely 3.74% of the free cash flow producing stocks we're observing.
- NVO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 58.47% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 294% |
| 1% | 298% |
| 2% | 302% |
| 3% | 306% |
| 4% | 310% |
| 5% | 314% |
Want more companies with a valuation profile/forecast similar to that of Novo Nordisk A S? See INVA, UHS, ARA, ALXN, and ANTM.
Loading social stream, please wait...